Although postsynaptic glycine receptors (GlyRs) as ab heteromers attract considerable research attention, little is known about the role of presynaptic GlyRs, likely a homomers, in diseases. Here, we demonstrate that dehydroxylcannabidiol (DH-CBD), a nonpsychoactive cannabinoid, can rescue GlyR functional deficiency and exaggerated acoustic and tactile startle responses in mice bearing point mutations in a1 GlyRs that are responsible for a hereditary startle-hyperekplexia disease. The GlyRs expressed as a1 homomers either in HEK-293 cells or at presynaptic terminals of the calyceal synapses in the auditory brainstem are more vulnerable than heteromers to hyperekplexia mutation-induced impairment. Homomeric mutants are more sensitive to DH-CBD than are heteromers, suggesting presynaptic GlyRs as a primary target. Consistent with this idea, DH-CBD selectively rescues impaired presynaptic GlyR activity and diminished glycine release in the brainstem and spinal cord of hyperekplexic mutant mice. Thus, presynaptic a1 GlyRs emerge as a potential therapeutic target for dominant hyperekplexia disease and other diseases with GlyR deficiency. 
a r t I C l e S Glycine has been defined as a major inhibitory neurotransmitter in the spinal cord for nearly half a century 1 . The GlyRs are the last therapeutic orphan among members of the cysteine-loop ligand-gated ion channel superfamily that includes GABA A , nicotinic acetylcholine (nACh) and 5-HT 3 receptors. Native GlyRs may consist of either homomers or heteromers. Although all α subunits (α1, α2, α3 and α4) are capable of forming functional homomeric channels, the β subunit can form functional channels only after coassembly with the α subunits 2 . Postsynaptic GlyRs have been well defined as heteromeric α1β subunits because the β subunit binds to gephyrin, which is a postsynaptic scaffolding protein that is essential for the clustering and targeting of GlyRs in the postsynaptic membrane 3, 4 . These receptors are thought to be the primary target for several neurological diseases, such as pain, anxiety, drug addiction and hyperekplexia disease 5 .
Presynaptic GlyRs were first described in calyceal synapses in the medial nucleus of the trapezoid body (MNTB) in the rat brainstem 6 . These presynaptic GlyRs were subsequently found to be expressed in the spinal cord and ventral tegmental area 7, 8 . In contrast to postsynaptic heteromeric GlyRs, presynaptic GlyRs are likely formed by homomeric α subunits 7, 8 . A recent study characterized in detail the anatomical segregation of presynaptic and postsynaptic GlyRs in calyx of Held neurons from the auditory brainstem 9 . This study provided strong evidence to show that GlyRs at presynaptic terminals of calyceal synapses are composed of homomeric α1 subunits. Although presynaptic GlyRs have been proposed to modulate neurotransmitter release under physiological conditions, little is known about the roles of presynaptic GlyRs in pathological processes.
Missense point mutations in the human α1 GlyR subunit gene disrupt GlyR function and result in familial hyperekplexia-startle disease 10, 11 . Although rare, this disease is characterized by excessive startle reactions to unexpected auditory and tactile stimuli followed by muscle stiffness 12 . Among dozens of point mutations that are associated with hyperekplexia disease, the most frequently occurring mutation causing human dominant hyperekplexia disease is the R271Q or R271L mutation in the α1 GlyR subunit 13 . Mice carrying the R271Q mutation exhibit severe hypersensitivity to tactile and acoustic stimuli, closely resembling human startle disease 14 . In addition to the mice carrying R271Q, other lines of genetically engineered mice carrying Q266I, S267Q or M287L mutations in the α1 subunit also display hyperekplexic behaviors 15, 16 . Despite overwhelming evidence for the functional deficiency of GlyRs in startle disease, current therapeutic agents do not target GlyRs 12 . In addition, the role of presynaptic GlyRs in startle disease has been largely ignored, as our knowledge about presynaptic GlyRs is very limited.
Allosteric positive modulators of GlyRs have been proposed to have therapeutic potential in the treatment of diseases with GlyR deficiency 17 . This appears to be the case, as recent studies have shown that a chemically modified cannabinoid, DH-CBD, can suppress acute and chronic pain by targeting α3 GlyRs specifically 18, 19 . We designed the present study to address two questions. Can DH-CBD treat exaggerated a r t I C l e S startle responses by restoring deficiency in GlyR function, and what is the role of presynaptic α1 GlyRs in hyperekplexia disease?
RESULTS

GlyR deficiency and exaggerated startle responses
The α1 R271Q mutation substantially impaired α1 GlyRs when expressed in HEK-293 cells. Glycine at 1 mM produced the maximal amplitude of I gly (glycine-induced maximal current) in HEK-293 cells expressing wild-type α1 GlyRs, whereas glycine at even 10 mM evoked relatively small currents in cells expressing the R271Q mutant receptors (α1 R271Q GlyRs) (Fig. 1a) . The R271Q mutation reduced the maximal amplitude of I gly (I max ) by 71% and significantly increased the glycine half-maximum effective concentration (EC 50 ) value (Fig. 1b) . In line with a previous study 14 , there was a pronounced reduction in both the frequency and amplitude of glycinergic spontaneous inhibitory postsynaptic currents (sIPSCs) in spinal slices from adult mice carrying the α1 R271Q missense mutation (Fig. 1c,d ). The R271Q mutant mice only survived as heterozygotes and displayed exaggerated startle response to both acoustic (Fig. 1e) and air-puff (Fig. 1f) stimuli. However, these hyperekplexic mice could be trained to perform at a level similar to their wild-type littermates in the rotarod test when they were handled gently and carefully (Supplementary Fig. 1 ).
DH-CBD restores GlyR deficiency-induced behaviors
DH-CBD is a synthetic cannabinoid that is slightly modified from CBD, which is the major nonpsychoactive component of marijuana (Fig. 2a) . DH-CBD has been shown to be more efficacious than CBD in potentiating I gly in HEK-293 cells expressing GlyRs and in suppressing pain hypersensitivity in mice through a GlyR-dependent mechanism 18 . We applied DH-CBD continuously for at least 5 min with intermittent applications of glycine in our electrophysiological experiments. DH-CBD at 10 µM substantially recovered the glycine I max in HEK-293 cells expressing α1 R271Q mutant GlyRs (Fig. 2a) . DH-CBD at 10 µM significantly reduced the glycine EC 50 value and increased the maximal I gly value for the α1 R271Q GlyRs (Fig. 2b) . The rescue of α1 R271Q mutant GlyR deficiency was dependent on DH-CBD concentrations over a range of 100 nM to 30 µM (Supplementary Fig. 2 ).
Next we examined whether DH-CBD can treat exaggerated startle reflexes in R271Q mutant mice. The most typical sign of α1 R271Q mutant mice that resembles human hyperekplexia is exaggerated startle reflexes to sudden noise (Supplementary Video 1). We measured the startle responses to different sound stimuli (80-120 dB) in α1 R271Q mutant mice and wild-type littermates. Wild-type mice were nearly insensitive to all levels of sound stimulus in the range 80-120 dB (Fig. 2c) . In contrast, α1 R271Q mutant mice exhibited exaggerated startle reflexes to the sound stimulus at all intensity levels (Fig. 2c) . For instance, the average values of startle responses to the acoustic sound stimulus (120 dB) were 135 ± 42 mV (mean ± s.e.m.) in the wild-type mice and 1,656 ± 222 mV in the α1 R271Q mutant mice. Intraperitoneal injection of DH-CBD inhibited the exaggerated startle response of α1 R271Q mutant mice in a dose-dependent manner ( Fig. 2c and  Supplementary Video 2) . Similarly, α1 R271Q mutant mice displayed exaggerated responses to tactile air-puff stimuli, suggesting that there is a deficiency in sensory-motor reflexes at the spinal level in these mice (Fig. 2d) . This tactile-induced exaggerated reflex was significantly suppressed by intraperitoneal injection of DH-CBD at 50 mg per kg body weight (Fig. 2d) . Similarly, these mice were supersensitive to touching and handling, as they displayed hind feet clenching behavior and exaggerated tremors when picked up by the tail (Fig. 2e) . Intraperitoneal injection of DH-CBD at 30 mg per kg body weight markedly alleviated this symptom. Whereas wild-type mice righted themselves in less than 1 s, α1 R271Q mutant mice needed more than 20 s to get back on their feet (Fig. 2f,g and Supplementary Video 3). Intraperitoneal injection of DH-CBD reversed the delay of righting reflex in α1 R271Q mutant mice in a concentrationdependent manner (Fig. 2f,g and Supplementary Video 4) . DH-CBD restoration: a site-and genotype-specific effect We next constructed eight additional point mutations in the α1 GlyR. Each of these mutations has been found to cause dominant familial startle disease in rodents or humans 11, 14, 16 . We found that all of these point mutations increased glycine EC 50 values (Fig. 3a) . DH-CBD significantly reduced glycine EC 50 values in seven of nine hyperekplexic mutant receptors when expressed in HEK-293 cells (Fig. 3a) . However, the impact of hyperekplexic mutations on the glycine I max appeared to be less consistent and varied substantially (Fig. 3b) . For instance, the S270T and M287L mutations resulted in an increase of glycine EC 50 values, whereas these mutations did not significantly alter the glycine I max when expressed in HEK-293 cells (P S270T = 0.75, t(14) = 0.32; P M287L = 0.81, t(14) = 0.25; unpaired t test). DH-CBD either partially or totally rescued the reduced glycine npg a r t I C l e S I max of the R218Q, R271Q and K276E mutants but did not significantly affect those of the other hyperekplexic mutant receptors. Thus, DH-CBD appeared to rescue the glycine EC 50 in an extent that was more consistent than its rescue of the glycine I max of hyperekplexic mutant receptors. In addition, two mutant α1 GlyRs, α1 Q266I and α1 S267Q, were completely insensitive to DH-CBD, suggesting that the rescue of GlyR dysfunction by DH-CBD is site specific. We next asked whether the efficacy of the rescue of GlyR function by DH-CBD is correlated with its restoration of exaggerated startle behaviors. We therefore collected four individual mouse lines that carry DH-CBD-sensitive (α1 R271Q and α1 M287L) or DH-CBDinsensitive (α1 Q266I and α1 S267Q) point mutations. Consistent with previous observations [14] [15] [16] , all four heterozygous mutant mouse lines showed significantly increased startle responses to sound stimuli at 120 db (Fig. 3c) . Intraperitoneal injection of DH-CBD (50 mg per kg body weight intraperitoneally (i.p.)) inhibited the startle response in both the α1 R271Q and α1 M287L mutant mice (Fig. 3c) . In contrast, the α1 S267Q and α1 Q266I mutant mice were insensitive to inhibition of the startle response by DH-CBD. Strychnine at 100 nM produced a rightward, parallel shift in the glycine concentrationresponse curve of wild-type α1 GlyRs expressed in HEK-293 cells (Supplementary Fig. 3a) . In line with a previous study 20 , strychnine (1.0 mg per kg body weight i.p.) increased the startle response in wild-type C57BL/6J mice (Supplementary Fig. 3b ). DH-CBD did not significantly alter strychnine-induced in vitro or in vivo effects. There was a strong correlation between the efficacy of the restoration of GlyR dysfunction by DH-CBD in vitro and the efficacy of the restoration of exaggerated startle behaviors by DH-CBD in vivo ( Fig. 3d ; γ 2 = 0.93, P = 0.0005, linear regression).
b subunit partially reduces mutant a1 GlyR deficiency The addition of β subunits rescued the α1 R271Q mutation-induced deficiency in HEK-293 cells coexpressing the β subunit with the α1 R271Q subunit (Fig. 4a) . This rescue was dependent on the ratio of the β and α1 R271Q subunits (Fig. 4b) . Increasing the ratio of the β subunit relative to the α1 R271Q mutant subunit transfected into cells decreased the glycine EC 50 value and increased the glycine I max . Coexpression of the β subunit with the α1 R271Q mutant subunit in a ratio of 3:1 completely rescued the impaired maximal efficacy of glycine. Conversely, the β subunit did not alter the expression levels of GlyR proteins at the cell surface ( Supplementary Fig. 4) , suggesting that the rescue induced by the β subunit is not due to alteration of receptor trafficking and receptor protein translation.
Similar to its rescue of the deficiency in α1 R271Q mutant receptors, the β subunit also rescued the deficiency in GlyR function caused by the other hyperekplexic mutations when coexpressed with each of eight hyperekplexic α1 mutant receptors (Fig. 4c) . Compared to homomeric α1 mutants, heteromeric α1β mutant GlyRs were either less sensitive or insensitive to DH-CBD (Fig. 4d) . Addition of the β subunit also rescued the reduced glycine I max of most, but not all, mutant receptors (Fig. 4e) . Conversely, DH-CBD did not significantly alter the glycine I max for these heteromeric mutant α1β GlyRs (Fig. 4f) .
DH-CBD rescues diminished spinal glycine release
Our above-described data suggest that GlyR homomers, but not heteromers, are the receptors that are most sensitive to cannabinoids. This idea favors a hypothesis that presynaptic, but not postsynaptic, GlyRs are the primary therapeutic target for cannabinoid treatment of exaggerated startle disease. To test this hypothesis, we first examined the effects of DH-CBD on glycinergic transmission by recording glycinergic sIPSCs in spinal cord slices of adult heterozygous α1 R271Q mutant and wild-type mice. Although the frequency and amplitude of the glycinergic sIPSCs were profoundly reduced in the mutant mice, bath application of DH-CBD at 20 µM increased only the diminished frequency but not the amplitude of a r t I C l e S the glycine sIPSCs ( Fig. 5a ). This suggests that DH-CBD rescues glycinergic deficiency by targeting presynaptic GlyRs. Unlike the postsynaptic GlyRs that typically hyperpolarize mature neurons after activation, stimulation of presynaptic GlyRs leads to depolarization of presynaptic terminals and an increase in glycine release due to chloride efflux 6, 7 . To further address whether DH-CBD acts on presynaptic glycinergic activity, we examined glycinergic miniature IPSCs (mIPSCs) in spinal dorsal horn neurons of α1 R271Q mice. To record glycinergic mIPSCs, we added tetrodotoxin (TTX; 1 µM) to the external solution in addition to glutamate and GABA A npg a r t I C l e S receptor antagonists. Similar to our observation with the glycinergic sIPSCs, DH-CBD profoundly increased the frequency, but not the amplitude, of the glycinergic mIPSCs in spinal slices from R271Q mutant mice (Fig. 5b) . The cumulative probability analysis of glycinergic mIPSCs revealed that DH-CBD shifted the distribution pattern of the inter-event interval, but not the amplitude, of the mIPSCs to the left (Fig. 5c) . We next tested the effect of DH-CBD on the pairedpulse ratio (PPR) of evoked glycinergic IPSCs in α1 R271Q spinal slices ( Fig. 5d) and found that DH-CBD significantly increased the PPR, suggesting a mechanism involving presynaptic modulation of GlyRs. The restoration of the deficiency in glycinergic transmission by DH-CBD appeared to be point-mutation specific, as DH-CBD did not alter the diminished frequency or amplitude of glycinergic sIPSCs in spinal slices from α1 Q266I mutant mice (Supplementary Fig. 5 ). This observation is in line with our previous observation that potentiation of hyperekplexic mutant GlyRs by DH-CBD is a site-specific effect. This surprising finding reveals a presynaptic mechanism for modulation of GlyRs by DH-CBD. To further test this idea, we applied a low concentration of picrotoxin (PTX) in an attempt to differentiate the presynaptic from the postsynaptic effect of DH-CBD on GlyRs. Low concentrations of PTX have been shown to preferentially inhibit homomeric α GlyRs without altering heteromeric αβ GlyRs that are expressed in HEK-293 cells 21, 22 . Similarly, PTX at low doses has also been found to selectively affect presynaptic GlyRs, which are likely homomers, in the spinal cord and brainstem 7, 9, 23 . We first examined the sensitivity of homomeric and heteromeric α1 R271Q mutant GlyRs to PTX-induced inhibition when expressed in HEK-293 cells. The homomeric α1 R271Q GlyRs were substantially more sensitive than were heteromeric α1 R271Qβ receptors to PTX-induced inhibition (Fig. 5e) .
For example, PTX at 30 µM significantly reduced the I gly by 55% in cells expressing α1 R271Q mutant homomers, (P = 0.0072, t(10) = 3.36, unpaired t test) whereas PTX at this dose had no effect on the I gly in cells expressing α1 R271Qβ1 mutant heteromers. This finding is in line with the idea that PTX at low concentrations (30 µM) preferentially inhibits homomeric or presynaptic GlyR activity. We next tested whether PTX at 30 µM can block the effect of DH-CBD on glycinergic sIPSCs, as DH-CBD similarly potentiated the frequencies of both glycinergic sIPSCs and glycinergic mIPSCs in spinal slices from α1 R271Q mice. In these slices, PTX at 30 µM completely eliminated the DH-CBD-induced potentiating effect on glycinergic sIPSC frequency (Fig. 5f) . In contrast, PTX did not significantly alter glycinergic sIPSC amplitude in the α1 R271Q spinal slices (P = 0.91, t(14) = 0.11, unpaired t test; Supplementary Fig. 6 ).
DH-CBD selectively rescues presynaptic GlyR deficiency
The calyx of Held is one of very few sites in the mammalian CNS at which direct recording of presynaptic channel conductance can be achieved 24 . The calyx of Held and its postsynaptic target, the MNTB, function as a critical relay in the brainstem auditory circuitry. Moreover, these calyceal terminals seemed to be an ideal preparation for us to study homomeric α1 subunits because they lack the β, α2 and α3 GlyR subunits 9 . We next recorded I gly using whole-cell patch clamps from both presynaptic and postsynaptic terminals in calyx of Held neurons from postnatal (P) 12-18 mice (Fig. 6a) . Application of 1 mM glycine evoked strychnine-sensitive and nearly maximal currents in postsynaptic MNTB principal neurons after P12 in wildtype mice (Fig. 6b) . Conversely, there was no detectable current when we applied 3 mM of glycine to calyceal terminals from P12 mice. The I gly became detectable in only 30% of calyceal terminals from npg a r t I C l e S P14 mice, and the amplitude of I gly reached a maximum after P16. This expression pattern is coincident with the timing of when the α1 subunits emerge and replace embryonic-dominant α2 subunits in the brainstem and spinal cord 2 . A previous study reported a very similar observation that presynaptic GlyR activity in the rat calyx depends on developmental stage 25 . Among four mutant mouse lines, only the M287L line can yield homozygous offspring. These mutant homozygous mice displayed seizure-like behaviors in response to acoustic and tactile stimuli after P14 (Supplementary Fig. 7a ). This abnormal behavior in the mutant mice (P16-P20) was fully reversed shortly after intraperitoneal injection of DH-CBD (50 mg per kg body weight) ( Supplementary  Fig. 7b ). In calyceal neurons isolated from homozygous M287L mice at P16-P18, the M287L mutation substantially impaired the function of presynaptic GlyRs (Fig. 6c) . Both the glycine I max and the apparent glycine affinity of presynaptic GlyRs from the M287L mutant mice were significantly reduced as compared with presynaptic GlyRs from their wild-type littermates (P EC50 = 0.0137, t(11) = 2.93; P Imax = 0.007, t(11) = 3.31, unpaired t test). In contrast, the M287L point mutation did not significantly alter the functionality of postsynaptic GlyRs in principal neurons (Fig. 6d) . DH-CBD at 10 µM significantly enhanced the average amplitude of the I gly recorded in presynaptic M287L terminals from 65 ± 15 pA (mean ± s.e.m.) to 181 ± 43 pA (Fig. 6e) . In contrast, DH-CBD did not significantly alter the postsynaptic I gly recorded in MNTB neurons from M287L mutant mice (Fig. 6f) . This result is consistent with our observation that the homomeric M287L mutant receptor, but not its heteromeric counterpart, is a cannabinoid-sensitive receptor.
Thus, nine hyperekplexic mutant α1 GlyRs can be classified as cannabinoid-sensitive and cannabinoid-insensitive receptors on the basis of their responses to cannabinoid potentiation of I gly and their rescue of startle behavior (Supplementary Fig. 8a) . Addition of the β subunits alone can substantially rescue the disrupting effect induced by all startle dominant mutations in the α1 subunits (Supplementary Fig. 8b) . Cannabinoids appear to restore the glycinergic dysfunction induced by hyperekplexic point mutations in homomeric α1 GlyRs, which are most likely located in presynaptic sites (Supplementary Fig. 8c ).
DISCUSSION
Despite abundant evidence for presynaptic GlyRs in the CNS, it is far from clear to what extent they have a role in physiological and pathological processes. This study highlights the potential importance of presynaptic GlyRs in both the pathophysiological mechanisms and therapeutic targets of dominant hyperekplexia disease. First, hyperekplexic point mutations in the α1 subunits disrupted the function of homomers more substantially than heteromers when expressed in HEK-293 cells and in segregated presynaptic and postsynaptic sites of calyceal and MNTB synapses. Second, hyperekplexic mutant homomers were more sensitive than mutant heteromers to DH-CBD-induced rescue. Third, DH-CBD potentiated only presynaptic homomeric α1 GlyRs without significantly altering postsynaptic GlyR activity in the calyx of Held of the auditory brainstem from hyperekplexic mutant mice. Consistent with this observation, DH-CBD preferentially rescued the diminished frequencies without significantly affecting the amplitudes of glycinergic sIPSCs and mIPSCs in spinal cord slices. Such rescue by DH-CBD was abolished completely by PTX at a concentration that preferentially blocked homomeric GlyRs, suggesting that DH-CBD rescue is mediated by presynaptic GlyRs. Fourth, an increase in the PPR induced by DH-CBD indicates an enhanced probability of neurotransmitter release in spinal cord slices of adult hyperekplexic mutant mice.
One could also argue that extrasynaptic GlyRs may be a target of hyperekplexia disease and DH-CBD. However, there is no good evidence for homomeric extrasynaptic α1 subunits. Most extrasynaptic GlyRs that have been characterized are homomeric α2 subunits in the brain during early developmental stages 2 . Conversely, extrasynaptic GlyRs in the brainstem are α1β heteromers 9 . These receptors are usually localized in either postsynaptic or presynaptic soma but not at presynaptic terminals 4, 9 . Our previous studies have shown that the α3 GlyRs are the targets of cannabinoids in the treatment of acute and chronic pain 18, 19 . This raises the question of whether the α3 subunit is also involved in the rescue by DH-CBD of hyperekplexic npg a r t I C l e S mutation-induced in vivo effects. It is unlikely that this is the case. Pain sensitivity to thermal stimuli is unchanged in R271Q mutant mice 26 , suggesting that there is no α3 GlyR deficiency-dependent behavioral change in these mice. Although DH-CBD can potentiate both wild-type α1 and α3 GlyRs, DH-CBD does not affect the baseline of either locomotor activity or startle responses in normal mice 18, 19 . In this regard, the potentiation of the α3 GlyRs by DH-CBD probably does not contribute to its rescue of exaggerated startle responses in α1 R271Q mutant mice. Consistent with recent studies 27, 28 , coexpression of the β subunits partially but markedly restored the functional deficiency in some hyperekplexic mutant GlyRs expressed in HEK-293 cells. Our data also suggest that homomeric-like presynaptic α1 GlyRs in native neurons sustain more channel-function damage as a result of hyperekplexia mutations than do heteromeric postsynaptic GlyRs. In general, these mutant homomers were more sensitive to rescue by DH-CBD. One hypothesis for this β subunit-dependent rescue is that a cluster of amino acids in the transmembrane domains of the β subunit may shield or compromise the gating impairment from hyperekplexic point mutations in the α1 subunit 27 . There is strong evidence to indicate a reduction of GlyR function in both chronic inflammatory and neuropathic pain in animals 29, 30 . Yet the role of presynaptic GlyRs in the regulation of pain transmission is unclear. Future studies should be carried out to determine whether presynaptic GlyRs are a potential target in chronic pain. We emphasize the presynaptic GlyRs in this study because the effect of DH-CBD on glycinergic input is presynaptic. In addition to the deficiency in presynaptic GlyR function (diminished glycine release), we also observed postsynaptic GlyR deficiency (reduced amplitude of glycinergic IPSCs) in spinal cord slices from R271Q mice. Thus, both impaired presynaptic and postsynaptic α1 GlyRs should account for the diminished glycinergic synaptic transmission caused by the R271Q mutation.
Hyperekplexia is usually introduced as a neuromotor disorder. However, there is a substantial underestimation of the impact of sensory dysfunction in this disease because of a loss of glycinergic innervation and transmission either in sensory neurons or from sensory neurons to motor neurons in the spinal cord. This underestimation could be present especially in patients with hyperekplexia bearing dominant mutations in the α1 subunits. These patients usually display hyper-reflexia and exaggerated startle responses to noise, tactile stimuli (such as air), handling (feeding or touching the head or nose) and even visual stimuli shortly after birth [31] [32] [33] . It appears that an increase in acoustic startle responses in hyperekplexia mutant mice does not always extend to more general motor behaviors such as balance and coordination in a rotarod test, as has been reported in previous studies and in our current study 15 . This finding strongly suggests that disinhibition by diminished glycinergic input is a major cause of hyperekplexia. Consistent with this notion, hyperekplexia mutations largely impaired the function of α1 GlyRs expressed at the presynaptic terminals of auditory brainstem and spinal dorsal horn neurons. Conversely, DH-CBD restored glycinergic transmission deficiency in both the brainstem and spinal cord by targeting presynaptic α1 GlyRs, at least in part.
There are a few hyperekplexic mutations that have been detected in postsynaptic proteins such as gephyrin and the GlyR β subunit 11, 34 . However, about 35% of patients with hyperekplexia do not carry mutations in genes encoding postsynaptic proteins such as gephyrin and the GlyR β subunits 13 . In addition, most hyperekplexic mutations occurring in the α1 subunits are linked to dominant familial startle disease, whereas mutations detected in the β subunit and glycine transporter genes are inherited principally in a recessive startle disease 11, 35, 36 . In addition to R271Q, five additional cannabinoidsensitive mutants tested in this study are inherited in human dominant hyperekplexia disease 11 . The majority of these mutants, such as V260M, P250T, S270T and R271Q, were very sensitive to rescue by DH-CBD when expressed as homomers but were less sensitive or insensitive when coexpressed with the β subunits as heteromers. In this regard, the notion that presynaptic GlyRs are an important therapeutic target should be applicable to dominant familial hyperekplexia. However, this hypothesis should be tested further once a genetic or pharmacological approach that is selective for the homomeric α1 subunit becomes available.
Therapeutic mechanisms and applications of nonpsychoactive cannabinoids have become renewed topics of recent research 17, 37 . The results presented here reveal a new potential for nonpsychoactive cannabinoids in the treatment of a severe hereditary neurological disease. Unlike GABA A receptor modulators that are plagued by various side effects 38 , DH-CBD does not produce major psychoactive or sedative effects even at high concentrations 19 . In addition, clonazepam, a commonly used agent in the treatment of hyperekplexia, is not always effective in the control of some symptoms in this disease 39 . More than 30 hyperekplexia missense, nonsense and frameshift mutations in the α1 GlyRs have been found to be linked to hyperekplexia disease 11 . Our data suggest that DH-CBD targets cannabinoid-sensitive GlyRs specifically, which are likely to be homomers located at presynaptic sites. It is worth noting that the M287L mutation produced more functional deficiency of GlyRs when expressed in calyceal neurons than in HEK-293 cells. This is consistent with a recent study that showed decreased glycine-mediated currents in isolated neurons of the brain stem from M287L mutant mice 40 . One possible explanation for this discrepancy is that a neuron-specific post-translational modification may alter the sensitivity of GlyRs to hyperekplexic mutations in vivo. This idea is supported by a previous study that showed different functional properties of the R271Q mutant α1 GlyR receptors when expressed in dorsal horn neurons and HEK-293 cells 41 .
Taken together, we provide new evidence showing that presynaptic GlyRs are an emerging target for the mechanism and therapeutics of hyperekplexia disease. These presynaptic-like GlyRs have been proposed to have a role in ethanol action and reward mechanisms in the brain 8, [42] [43] [44] . Thus, these GlyRs that reside at presynaptic terminals may represent a previously underestimated target with potential importance for various diseases involving GlyR deficiency or GlyR signaling pathways.
METHODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METHODS
Animals. Unless otherwise indicated, male hyperekplexic GlyR mutant mice and their wild-type littermates weighing between 20 and 28 g (7-12 weeks old) were used in all experiments. The animals bred specifically for this study were backcrossed to C57BL/6J mice for at least six generations. They were housed two mice per cage on a 12 h light, 12 h dark cycle and were not used in different behavioral tests. All behavioral tests were double blind and performed during the light cycle (9:00 a.m. to 5:00 p.m.). These mice were adapted to the experimental environment for at least 2 h before the tests. All animal studies were carried out under protocols approved by the Animal Care and Use Committees of the University of Pittsburgh, the University of Texas MD Anderson Cancer Center and the National Institute on Alcohol Abuse and Alcoholism. The α1 Q266I, α1 M287L, α1 S267Q and α1 R271Q mutant mice were generated as previously described 14, 16, 40, 45 . All genetically engineered mice studied were heterozygous for the mutant α1 subunit. Genotyping of the α1 Q266I mutant mice was done using the following primers: forward: 5′-GCCTGCTCATCGTCATCCTG-3′; reverse: 5′-CCAATCTGATCTGTGCAATCCT-3′. Genotyping of the α1 S267Q mutant mice was done using the following primers: forward: 5′-GCTT TAACTTCTGCCCTATGG-3′; reverse: 5′-GTTGTTGTTAACTTGTTTAT TG-3′. Genotyping of the α1 M287L mutant mice was done using the following primers: forward: 5′-GAATCTTCCAGGCAACATTTCAG-3′; reverse: 5′-AGTATCCCACCAAGCCAGTCTTT-3′. Genotyping of the α1 R271Q mutant mice was done using the following primers: forward: 5′-CTCATCTTTGA GTGGCAGGA-3′; reverse: 5′-GCATCCATGTTGATCCAGAA-3′. Wild-type mice and mutant (α1 R271Q, α1 M287L, α1 Q266I and α1 S267Q) heterozygous mice used for the behavior experiments were produced from heterozygous and corresponding wild-type breeding pairs.
Site-directed mutagenesis. Point mutations of human α1 GlyR were introduced using a QuikChange Site-Directed Mutagenesis kit (Stratagene). The authenticity of the DNA sequence through the mutation sites was confirmed by double-stranded DNA sequencing using a CEQ 8000 Genetic Analysis System (Beckman Coulter, Inc.).
electrophysiological recording. HEK-293 cell transfection and recording.
HEK-293 cells were cultured as described previously 46 . Plasmid cDNAs coding for wild-type and mutant GlyR subunits were transfected using the SuperFect Transfection kit (Qiagen, Hidden, CA). Electrophysiological recordings were carried out 2 d after transfection. HEK-293 cells were treated with 0.25% (wt/vol) trypsin and 0.53 mM ethylenediaminetetraacetic acid 2 h before recording. The HEK-293 cells were lifted and continuously superfused with a solution containing 140 mM NaCl, 5 mM KCl, 1.8 mM CaCl 2 , 1.2 mM MgCl 2 , 5 mM glucose and 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (pH 7.4 with NaOH, ~340 mOsm with sucrose). Patch pipettes (3-5 MΩ) were filled with intracellular solution that contained 120 mM CsCl, 4 mM MgCl 2 , 10 mM ethyleneglycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA), 10 mM HEPES, 0.5 mM Na-GTP and 2 mM Mg-ATP (pH 7.2 with CsOH, ~280 mOsm). Membrane currents were recorded in the whole-cell configuration using an Axopatch 200B amplifier (Axon) at 20-22 °C. Cells were held at -60 mV unless otherwise indicated. Data were acquired using pClamp 9.2 software (Molecular Devices, Sunnyvale, CA). Data were filtered at 1 kHz and digitized at 2 kHz. Bath solutions were applied through three-barrel square glass tubing (Warner Instrument, Hamden, CT) with a tip diameter of ~700 µm. Drugs were applied using a Warner fast-step stepper motor-driven system. The solution exchange time constants were ~4 ms for an open pipette tip and 4-12 ms for whole-cell recordings.
Spinal cord slice preparation and recording. Lumbar spinal cord slices at the L5-L6 level were prepared from adult mice as we described previously 47, 48 . The lumbar spinal cord was removed through laminectomy during isofluraneinduced anesthesia and sliced (400 µm) using a vibratome. The slices were superfused continuously with artificial cerebrospinal fluid containing (in mM) 117.0 NaCl, 3.6 KCl, 1.2 MgCl 2 , 2.5 CaCl 2 , 1.2 NaH 2 PO 4 , 11.0 glucose and 25.0 NaHCO 3 (bubbled with 95% O 2 and 5% CO 2 ). Neurons in the lamina II of the spinal cord were visualized using a fixed-stage microscope (BX50WI, Olympus, Tokyo, Japan) with differential interference contrast and infrared illumination. We obtained all whole-cell patch-clamp recordings at 34 °C using glass pipettes filled with a solution containing (in mM) 110 Cs 2 SO 4 , 5 tetraethylammonium ion, 2.0 MgCl 2 , 0.5 CaCl 2 , 5.0 HEPES, 5.0 EGTA, 5.0 ATP-Mg, 0.5 Na-GTP and 10 lidocaine N-ethyl bromide, adjusted to pH 7.2-7.4 with 1 M CsOH (290-300 mOsm). Spinal slices were recorded at a holding potential of 0 mV. DH-CBD was applied by puff application directly to the recorded neuron using a positive pressure system (4 PSI, 15 ms; Toohey Company, Fairfield, NJ). Glycinergic sIPSCs were recorded in the presence of 10 µM 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), 10 µM bicuculline and 50 µM AP5 (d(-)-2-amino-5-phosphonovaleric acid), which were bath applied during the recording period. Glycinergic mIPSC were recorded in the presence of TTX (1 µM). The input resistance was monitored continuously, and the recording was abandoned if the resistance changed more than 15%. All spinal slice recordings were performed under a double-blind condition. Data acquisition and analysis of postsynaptic currents were done as described previously 47, 48 .
Calyceal slice preparation and recording. Parasagittal brainstem slices (100-µm thick) containing the MNTB were prepared from 12-to 18-day-old mice of either sex using a vibratome (7000 SMZ, Campden Instrument). For the dissection and storage of slices, we used a solution containing (in mM) 95 NaCl, 25 NaHCO 3 , 25 glucose, 50 sucrose, 2.5 KCl, 1.25 NaH 2 PO 4 , 0.1 CaCl 2 , 3 MgCl 2 , 0.4 ascorbic acid, 3 myo-inositol and 2 sodium pyruvate (95% O 2 and 5% CO 2 ). The slices were incubated for 30 min at 37 °C and then held at room temperature (22-24 °C) . Whole-cell current recordings were made from calyx of Held terminals and principal neurons of the MNTB. The sampling interval and filter setting were 20 µs and 2.9 kHz, respectively. Cells were visualized by differential interference contrast microscopy through a 40× water-immersion objective using an upright Olympus microscope. All experiments were made with the EPC-10 amplifier. The holding potential was 0 mV. The bath solution (22−24 °C) contained (in mM) 125 NaCl, 2. Startle response measurement. Acoustic startle response test. Startle responses were measured using SR-LAB test stations and software (San Diego Instruments, San Diego, CA). The method of startle response measurement was modified from a previous study 16 . Briefly, test stations were both standardized and calibrated. Individual mice were then placed in the Plexiglas holding cylinder for a 5-min acclimation period. A background noise level of 70 dB was maintained over the duration of the test session. The recording period of acoustic startle responses consisted of six blocks. Each block consisted of six trials: one control trial with no stimulus (baseline) and five trials with a single 40-ms sound of 80, 90, 100, 110 or 120 dB presented in random order with a 10-to 20-s intertrial interval. The entire session comprised 36 trials and took ~15 min. The startle amplitude was measured every 1 ms over a 65-ms period beginning at the onset of the startle stimulus trial. The startle response was identified as the maximum startle amplitude (V m ) to a given stimulus minus the V m to no stimulus (baseline).
Tactile startle response test. The San Diego Instruments, Inc. (San Diego, CA) SR-LAB system was used to deliver the tactile air-puff stimulus and measure the flinch response of the mouse. The mouse was placed in a Plexiglas cylinder, which was located within a ventilated sound-attenuating chamber to reduce noise contamination, and left undisturbed for a 5-min acclimation period. Air-puff stimuli of 1.5 or 5 PSI controlled by a regulator were delivered to the backs of the mice for a duration of 100 ms. Vibrations occurring in the Plexiglas cylinder caused by whole-body startle responses were recorded over 200 ms after presentation of the stimulus and were transduced into analog signals by a piezoelectric unit attached to the platform. The entire session comprised six trials with a 1-to 2-min intertrial interval.
Righting reflex test. Each mouse was placed on its side on a flat surface, and the time it took to turn over to rest in the normal position with all four feet on the ground was recorded. The cutoff time was set as 30 s. This experiment was repeated three times, and the average time recorded was identified as the righting reflex time. 
